Tenalisib for metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with triple-negative breast cancer (confirmed by biopsy).
- You have metastatic breast cancer (cancer that has spread to other parts of the body).
- You have had 1 to 3 prior chemotherapy treatments for metastatic cancer.
- You have at least one tumor that can be measured on scans (tumors only in the bones do not count).
- You are up and about for at least half of your waking hours (ECOG performance status 0 to 2).
- You have adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC5513, given alone or with another drug called QL1706, for people with advanced or metastatic triple-negative breast cancer (TNBC) that has worsened after at least one previous treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of two drugs—an antibody-drug conjugate that targets a protein on cancer cells and an immunotherapy that helps your immune system attack the tumor—for people with advanced triple-negative breast cancer that has already been treated. It aims to see if this combo can shrink tumors or slow the disease.
This trial tests a new oral medication called Zn-Telomir in patients with triple-negative breast cancer that has spread or cannot be surgically removed. The drug may help slow or shrink tumors in people whose cancer has grown despite prior treatments.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.